
|Articles|February 5, 2015
- Gastrointestinal Cancers (Issue 4)
- Volume 4
- Issue 1
Chemotherapy Treatment in Gastric Cancer
Author(s)Eric Van Cutsem, MD, PhD
Eric Van Cutsem, MD, PhD, discusses the challenges of using chemotherapy to treat patients with gastric cancer.
Advertisement
Eric Van Cutsem, MD, PhD, at University Hospitals Gasthuisberg/Leuven in Leuven, Belgium, discusses the challenges of using chemotherapy to treat patients with gastric cancer.
Clinical Pearls:
- Using trastuzumab or other anti-HER2 agents when treating patients with gastric cancer does not eliminate the need to use chemotherapy.
- Patients with gastric cancer are often in poor health to begin with and have low tolerance levels and fast occurrances of resistance after undergoing chemotherapy.
- There is room for growth and improvement in chemotherapy in order to determine if the treatments can contain less toxicities, which remains a challenge for patients in regards to their overall means of survival.
Articles in this issue
over 11 years ago
Expert Investigators Discuss Emerging Therapies for GI Cancersover 11 years ago
Predictors of Toxicity in Colon Cancer Treatment Identifiedover 11 years ago
Many Biliary Tract Cancers Harbor Actionable Mutationsover 11 years ago
Safety of Regorafenib Confirmed in Patients With mCRC and High PFSover 11 years ago
Pembrolizumab in Advanced Gastric Cancer Treatmentover 11 years ago
Onartuzumab for Gastroesophageal Adenocarcinomaover 11 years ago
FOLFOXIRI plus Bevacizumab for Metastatic Colorectal CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5

































